Cargando…
A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that infla...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207622/ https://www.ncbi.nlm.nih.gov/pubmed/25331066 http://dx.doi.org/10.1186/s13048-014-0100-8 |
_version_ | 1782341004436701184 |
---|---|
author | Tamura, Hiroshi Takasaki, Akihisa Nakamura, Yasuhiko Numa, Fumitaka Sugino, Norihiro |
author_facet | Tamura, Hiroshi Takasaki, Akihisa Nakamura, Yasuhiko Numa, Fumitaka Sugino, Norihiro |
author_sort | Tamura, Hiroshi |
collection | PubMed |
description | BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. METHODS: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2’-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups. RESULTS: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%, respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml). Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml). CONCLUSIONS: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the ovary in patients with endometriosis. |
format | Online Article Text |
id | pubmed-4207622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42076222014-10-28 A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis Tamura, Hiroshi Takasaki, Akihisa Nakamura, Yasuhiko Numa, Fumitaka Sugino, Norihiro J Ovarian Res Research BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. METHODS: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2’-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups. RESULTS: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%, respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml). Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml). CONCLUSIONS: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the ovary in patients with endometriosis. BioMed Central 2014-10-21 /pmc/articles/PMC4207622/ /pubmed/25331066 http://dx.doi.org/10.1186/s13048-014-0100-8 Text en © Tamura et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tamura, Hiroshi Takasaki, Akihisa Nakamura, Yasuhiko Numa, Fumitaka Sugino, Norihiro A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title | A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title_full | A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title_fullStr | A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title_full_unstemmed | A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title_short | A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis |
title_sort | pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in ivf-et patients with endometriosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207622/ https://www.ncbi.nlm.nih.gov/pubmed/25331066 http://dx.doi.org/10.1186/s13048-014-0100-8 |
work_keys_str_mv | AT tamurahiroshi apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT takasakiakihisa apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT nakamurayasuhiko apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT numafumitaka apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT suginonorihiro apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT tamurahiroshi pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT takasakiakihisa pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT nakamurayasuhiko pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT numafumitaka pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis AT suginonorihiro pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis |